# Junta clínica — PT-pseudo_95d3fd02d5e0 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_95d3fd02d5e0",
  "pid": "PT-pseudo_95d3fd02d5e0",
  "task": 1,
  "psa": 5.5,
  "age": 63,
  "months": 3,
  "pirads": "4",
  "psad": 0.11,
  "psav": 0.77,
  "psap": 5.4,
  "vol": 48.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.6454933,
  "medhx": "Type 2 diabetes, Coronary artery disease",
  "meds": "metformin, empagliflozin, aspirin 80 mg",
  "notes": "PSA 5.5 ng/mL. PI-RADS 4. PSAD 0.11. Prostate volume 48 mL. csPCa 0.65.",
  "pmhx": [
    "Type 2 diabetes",
    "Coronary artery disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "88 kg",
    "height": "181 cm",
    "bmi": "26.9",
    "bp": "160/82 mmHg",
    "hr": "66 bpm",
    "smoking": "Non-smoker",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "16 Feb 2025",
  "enc_ref": "Dr. K. Bakker (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical assessment required due to persistently elevated prostate-specific antigen levels and a previous biopsy confirming malignancy."
    },
    {
      "s": "History",
      "t": "A 63-year-old retired bus driver initially entered investigation in mid-2023 after PSA markers began climbing. He abstains from tobacco and alcohol entirely. His medical background includes type 2 diabetes, currently controlled with metformin and empagliflozin, alongside coronary artery disease managed via daily aspirin 80 mg. Severe lower urinary tract symptoms have persisted for years, yielding an IPSS score of 28 out of 35. He covers roughly 20 kilometres on his bicycle twice weekly. Quarterly consultations with a diabetes nurse remain routine, complemented by a recently finished six-session physiotherapy regimen for mechanical lower back pain. Chronic shoulder discomfort is also monitored through a specialized pain clinic. Widowed, he shares a home with his partner and maintains a flexible timetable that easily accommodates his outpatient visits."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Examination reveals a normal prostate profile; the gland is symmetrically enlarged with a smooth, firm consistency and lacks any palpable nodules or asymmetry. Vital parameters remain stable; blood pressure reads 160/82 mmHg while the cardiac rhythm is regular at 66 beats per minute. General observation notes a well-nourished individual free of acute distress, with clear pulmonary fields and consistent heart sounds upon auscultation."
    }
  ],
  "occupation": "retired bus driver",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Diabetes nurse — quarterly review",
    "Physiotherapy — lower back, six sessions",
    "Pain clinic — chronic shoulder pain"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Cycling 2x/week, ~20 km",
  "ipss": "IPSS score: 28/35 (severe LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_95d3fd02d5e0
Task: 1

Encounter: Urology - outpatient on 16 Feb 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 5.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.11 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 5.4 ng/mL
  - Prostate volume: 48.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6454933 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Coronary artery disease
  - Problem list / PMHx: Type 2 diabetes, Coronary artery disease
  - Current medication: metformin, empagliflozin, aspirin 80 mg
  - Allergies: NKA
  - Additional notes: PSA 5.5 ng/mL. PI-RADS 4. PSAD 0.11. Prostate volume 48 mL. csPCa 0.65.

Vitals: weight 88 kg, height 181 cm, BMI 26.9, BP 160/82 mmHg, HR 66 bpm. Smoking: Non-smoker.

Chief complaint: Clinical assessment required due to persistently elevated prostate-specific antigen levels and a previous biopsy confirming malignancy.

History: A 63-year-old retired bus driver initially entered investigation in mid-2023 after PSA markers began climbing. He abstains from tobacco and alcohol entirely. His medical background includes type 2 diabetes, currently controlled with metformin and empagliflozin, alongside coronary artery disease managed via daily aspirin 80 mg. Severe lower urinary tract symptoms have persisted for years, yielding an IPSS score of 28 out of 35. He covers roughly 20 kilometres on his bicycle twice weekly. Quarterly consultations with a diabetes nurse remain routine, complemented by a recently finished six-session physiotherapy regimen for mechanical lower back pain. Chronic shoulder discomfort is also monitored through a specialized pain clinic. Widowed, he shares a home with his partner and maintains a flexible timetable that easily accommodates his outpatient visits.

Physical examination: DRE: Examination reveals a normal prostate profile; the gland is symmetrically enlarged with a smooth, firm consistency and lacks any palpable nodules or asymmetry. Vital parameters remain stable; blood pressure reads 160/82 mmHg while the cardiac rhythm is regular at 66 beats per minute. General observation notes a well-nourished individual free of acute distress, with clear pulmonary fields and consistent heart sounds upon auscultation.

Patient info: retired bus driver; Widowed; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Cycling 2x/week, ~20 km; IPSS score: 28/35 (severe LUTS).

Recent other appointments: Diabetes nurse — quarterly review; Physiotherapy — lower back, six sessions; Pain clinic — chronic shoulder pain.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.48
  uncertainty  +/- 0.11 epistemic (95% band 0.27-0.68); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.43: PI-RADS 4, PSA 6.5, PSAD 0.11, age 64, DRE Normal -> DEFER (uncertain). He wrote: "Need initial ISUP grade and MRI in men on active surveillance."
  2. distance 0.57: PI-RADS 4, PSA 5.3, PSAD 0.092, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 65 years old patient"
  3. distance 0.87: PI-RADS 4, PSA 4.7, PSAD 0.07, age 59, DRE Normal -> DEFER (uncertain). He wrote: "PRADS 4 with low-PSA-density can be followed up, I need results of earlier biopsy to make a definite call"

PRECEDENT: DEFER (weighted vote 0.34 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the use of MRI-based indication for biopsy and the role of PI-RADS scores. "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy." This suggests that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of no biopsy because the guideline suggests that PI-RADS $\ge 3$ is used to trigger biopsy, which is relevant here. EXPERT-LIBRARY's precedent of DEFER is not decisive because the guideline suggests that the decision depends on risk factors like PSA density and PI-RADS score, which are present here.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the PSA velocity of 0.77 ng/mL/yr is a factor that must be weighed against the guideline's risk-adapted matrix.
laboratory_results - the PSA density: the PSA density of 0.11 ng/mL² is a factor that must be weighed against the guideline's risk-adapted matrix.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on the documented grade of the prior biopsy and the PSA velocity, as the guideline suggests these factors must be weighed against the imaging and density metrics.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size and zone, and whether it is compared against an earlier study, support a repeat biopsy?
  psa_trend (get_psa_trend) -> How should the PSA velocity of 0.77 ng/mL/yr be weighed against the guideline's risk-adapted matrix?
  previous_notes (get_previous_notes) -> What is the documented grade (Gleason/ISUP) of the prior biopsy, and is there a surveillance protocol?
  laboratory_results (get_lab_results) -> How should the PSA density of 0.11 ng/mL² be weighed against the guideline's risk-adapted matrix?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy?
  Q2. Does the documented grade of the prior biopsy meet the guideline threshold for treatment?
  Q3. How should the PSA velocity of 0.77 ng/mL/yr be weighed against the risk-adapted matrix?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "A discrete focus sits in the posterior right mid-gland peripheral zone, spanning 14 x 10 x 12 mm."

psa_trend
How should the PSA velocity of 0.77 ng/mL/yr be weighed against the guideline's risk-adapted matrix?: The PSA velocity of 0.77 ng/mL/yr is a factor that must be weighed against the guideline's risk-adapted matrix.

previous_notes
What is the documented grade (Gleason/ISUP) of the prior biopsy, and is there a surveillance protocol?: The documented grade (Gleason/ISUP) of the prior biopsy is not recorded, and there is no surveillance protocol mentioned.

laboratory_results
How should the PSA density of 0.11 ng/mL² be weighed against the guideline's risk-adapted matrix?: The PSA density of 0.11 ng/mL² is a factor that must be weighed against the guideline's risk-adapted matrix.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes provided sufficient context regarding the prior biopsy status.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 4 lesion in the right mid-gland peripheral zone, as per the radiology report.
PSA velocity of 0.77 ng/mL/yr, as this velocity must be weighed against the risk-adapted matrix.

AGAINST sampling this patient now
The documented grade (Gleason/ISUP) of the prior biopsy is not recorded, as per the previous notes.
The PSA density of 0.11 ng/mL² is a factor that must be weighed against the guideline's risk-adapted matrix.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 5.50 ng/mL over 5 points spanning 19 months; velocity +2.14 ng/mL per year; doubling time about 14 months.
PROJECTION at 6 months: 7.3 ng/mL, conformal 95% band 2.1-25.4.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.64
  uncertainty  +/- 0.08 epistemic (95% band 0.48-0.81), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.48  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.64  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.34  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.60 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: borderline. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have addressed the moderator's questions by providing information on the lesion size from the radiology report, the PSA velocity from the PSA trend, and noting that the documented grade of the prior biopsy and the PSA density are factors to be weighed against the guideline matrix.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a BIOPSY recommendation based on the weighted vote of EXPERT-FUSION, which carried the most weight. The retrieved findings—specifically the PI-RADS 4 lesion and the PSA velocity—support the need for further investigation, aligning with the fusion expert's suggestion.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy? This remains unanswered, as the previous notes stated the grade was not recorded.
Q2. Does the documented grade of the prior biopsy meet the guideline threshold for treatment? This cannot be answered without the grade from Q1.
Q3. How should the PSA velocity of 0.77 ng/mL/yr be weighed against the risk-adapted matrix? This is noted as a factor to be weighed but not explicitly resolved by the retrieved data.

WHAT CARRIES WEIGHT, AND WHY
The PSA velocity (0.77 ng/mL/yr) is critical because the EAU guideline explicitly states this velocity must be weighed against the risk-adapted matrix. The documented grade of the prior biopsy is also paramount as the protocol notes that if it is unrecorded, the indication stands.

MY SUGGESTION TO THE CHAIR
Given that the documented prior biopsy grade is missing, the decision remains ambiguous. However, the panel's weighted vote leans towards BIOPSY, supported by the PI-RADS 4 finding and the rising PSA velocity. Therefore, I suggest proceeding with a biopsy to establish the prior grade and further characterize the lesion.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

63y/o, PSA 5.5, PSAD 0.11, PI-RADS 4, prior positive biopsy with unrecorded ISUP grade. The lack of prior grade mandates sampling to determine management pathway. Low PSAD argues for observation, but the unrecorded prior grade makes biopsy necessary.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
